{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Autologous+fibroblasts", "query": { "intervention": "Autologous fibroblasts" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 39, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Autologous+fibroblasts&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-10T14:27:10.774Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00655356", "title": "Safety and Efficacy Study of Isolagen Therapy in the Treatment of Nasolabial Fold Wrinkles", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bilateral Nasolabial Fold Wrinkles" ], "interventions": [ { "name": "Autologous Human Fibroblasts (azficel-T)", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Castle Creek Biosciences, LLC.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 218, "start_date": "2006-11", "completion_date": "2009-05", "has_results": true, "last_update_posted_date": "2012-03-13", "last_synced_at": "2026-09-10T14:27:10.774Z", "location_count": 6, "location_summary": "Beverly Hills, California • San Diego, California • Snellville, Georgia + 3 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Snellville", "state": "Georgia" }, { "city": "San Antonio", "state": "Texas" }, { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00655356" }, { "nct_id": "NCT00004132", "title": "Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Drug/Agent Toxicity by Tissue/Organ", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Oral Complications", "Radiation Toxicity" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "palifermin", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "12 Years to 65 Years" }, "enrollment_count": null, "start_date": "2000-01", "completion_date": "2004-05", "has_results": false, "last_update_posted_date": "2013-06-26", "last_synced_at": "2026-09-10T14:27:10.774Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004132" }, { "nct_id": "NCT03005106", "title": "StrataGraft® Skin Tissue in the Promotion of Autologous Skin Regeneration of Complex Skin Defects Due to Thermal Burns That Contain Intact Dermal Elements", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Burn, Thermal" ], "interventions": [ { "name": "StrataGraft Skin Tissue", "type": "BIOLOGICAL" }, { "name": "Autograft", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Stratatech, a Mallinckrodt Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 71, "start_date": "2017-05-30", "completion_date": "2020-03-27", "has_results": true, "last_update_posted_date": "2021-07-14", "last_synced_at": "2026-09-10T14:27:10.774Z", "location_count": 16, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Orange, California + 13 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03005106" }, { "nct_id": "NCT00058799", "title": "Treating High Risk Leukemia With CD40 Ligand & IL-2 Gene Modified Tumor Vaccine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "Dose Level 1", "type": "BIOLOGICAL" }, { "name": "Dose Level 2", "type": "BIOLOGICAL" }, { "name": "Dose Level 3", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "75 Years", "sex": "ALL", "summary": "Up to 75 Years" }, "enrollment_count": 11, "start_date": "1999-06", "completion_date": "2010-06", "has_results": false, "last_update_posted_date": "2020-01-21", "last_synced_at": "2026-09-10T14:27:10.774Z", "location_count": 3, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00058799" }, { "nct_id": "NCT04213261", "title": "A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Recessive Dystrophic Epidermolysis Bullosa" ], "interventions": [ { "name": "FCX-007 (dabocemagene autoficel; see below for FCX-007 description)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Castle Creek Biosciences, LLC.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 6, "start_date": "2020-06-09", "completion_date": "2037-07", "has_results": true, "last_update_posted_date": "2026-03-18", "last_synced_at": "2026-09-10T14:27:10.774Z", "location_count": 5, "location_summary": "Stanford, California • Aurora, Colorado • Jacksonville, Florida + 2 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04213261" }, { "nct_id": "NCT01237951", "title": "High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myeloma" ], "interventions": [ { "name": "Palifermin", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Stem Cell Transplant", "type": "PROCEDURE" }, { "name": "G-CSF", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 75, "start_date": "2010-11-08", "completion_date": "2017-09-20", "has_results": true, "last_update_posted_date": "2020-05-05", "last_synced_at": "2026-09-10T14:27:10.774Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01237951" }, { "nct_id": "NCT03005054", "title": "StrataGraft® Skin Tissue as an Alternative to Autografting Full-thickness Complex Skin Defects", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Trauma-related Wound", "Burns", "Skin Wound" ], "interventions": [ { "name": "StrataGraft Skin Tissue", "type": "BIOLOGICAL" }, { "name": "Autograft", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Stratatech, a Mallinckrodt Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 3, "start_date": "2017-04-24", "completion_date": "2019-03-26", "has_results": true, "last_update_posted_date": "2021-08-03", "last_synced_at": "2026-09-10T14:27:10.774Z", "location_count": 4, "location_summary": "Phoenix, Arizona • Winston-Salem, North Carolina • Fort Sam Houston, Texas + 1 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Winston-Salem", "state": "North Carolina" }, { "city": "Fort Sam Houston", "state": "Texas" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT03005054" }, { "nct_id": "NCT03947450", "title": "Autologous Volar Fibroblast Injection Into the Stump Site of Amputees", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Amputation", "Skin Wound", "Stem Cell" ], "interventions": [ { "name": "Autologous Skin Fibroblasts", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 50, "start_date": "2019-09-05", "completion_date": "2028-04-01", "has_results": false, "last_update_posted_date": "2026-06-09", "last_synced_at": "2026-09-10T14:27:10.774Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03947450" }, { "nct_id": "NCT02810951", "title": "A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa (RDEB)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Epidermolysis Bullosa Dystrophica, Recessive" ], "interventions": [ { "name": "FCX-007", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Castle Creek Biosciences, LLC.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "7 Years", "maximum_age": null, "sex": "ALL", "summary": "7 Years and older" }, "enrollment_count": 6, "start_date": "2016-07-01", "completion_date": "2022-04-18", "has_results": true, "last_update_posted_date": "2023-02-08", "last_synced_at": "2026-09-10T14:27:10.774Z", "location_count": 2, "location_summary": "Stanford, California • Aurora, Colorado", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02810951" }, { "nct_id": "NCT01306019", "title": "Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "X-linked Severe Combined Immunodeficiency (XSCID)" ], "interventions": [ { "name": "Ex vivo culture and transduction of the patient's autologous CD34+ HSC with lentivirus vector VSV-G pseudotyped CL20- 4i-EF1alpha-hgammac-OPT vector", "type": "BIOLOGICAL" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Palifermin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "50 Years", "sex": "MALE", "summary": "2 Years to 50 Years · Male only" }, "enrollment_count": 40, "start_date": "2012-09-25", "completion_date": "2032-12-31", "has_results": false, "last_update_posted_date": "2026-09-08", "last_synced_at": "2026-09-10T14:27:10.774Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01306019" } ] }